TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00183365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Skills Training
Description: Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Skills Training
Description: Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protecting Families Program (PFP)
Description: Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
Study: NCT01135407

Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions.

Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.

Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
Study: NCT02915302

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent vaccine, No Preservative
Description: 0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative
Description: 0.5-mL, Intramuscular (2016-2017 formulation)
Study: NCT04288765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Only Product in Parenteral Dose Form
Description: Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab Only Product in Parenteral Dose Form
Description: Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly
Study: NCT03059069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chonline Alphoscerate
Description: Patients treated with Chonline Alphoscerate as add on therapy to their medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients maintain their medication with either Gliatamin or placebo for 6 months.
Study: NCT01189084

Intervention type: BIOLOGICAL
Intervention: Observational
Description: Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
Study: NCT00095732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally in either Size 2 or Size 5 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally in either Size 2 or Size 5 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally in either Size 2 or Size 5 capsules
Study: NCT00160784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: Randomized placement into 2 groups; arthroscopic manipulation or home therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic manipulation
Description: Manipulation of shoulder performed during arthroscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Shoulder exercise program performed at home that may increase shoulder function
Study: NCT02860780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ralimetinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ralimetinib
Description: Administered orally
Study: NCT03129880

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weekly Voice Therapy
Description: Participants will be randomized to receive weekly voice therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Voice Therapy
Description: Participants will be randomized to receive multiple sessions of voice therapy in one day.
Study: NCT00444899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Description: Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal follow-up
Description: Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
Study: NCT01886612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duo-STIM neuromuscular electrical stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Impulse System Model 6000
Study: NCT02198079

Intervention type: BIOLOGICAL
Intervention: Sputum
Study: NCT03809429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049 + GnRH agonist (GONAPEPTYL)
Description: Pre-filled injection pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999049 + GnRH antagonist (CETROTIDE)
Description: Powder and solvent for solution for injection
Study: NCT02480153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
Study: NCT02831803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 28 gm/day in single-serve package

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil
Description: 32 gm/day provided in 3, 34 ounce bottles
Study: NCT00737971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab intravitreal
Description: Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Bevacizumab
Description: Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
Study: NCT00512317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: liquid suspension dosed tid
Study: NCT03775070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: * Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition.
Study: NCT02258308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW intervention
Description: Home education and support for asthma self management
Study: NCT02935452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GENIE - social networking tool
Description: GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
Study: NCT00435591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: ampoule or premix bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: ampoule or premix bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: ampoule or premix bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: ampoule or premix bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: ampoule or premix bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: ampoule or premix bag
Study: NCT02618915

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX101
Description: solution for IV infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX101
Description: solution for IV infusion
Study: NCT01864057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiamine hydrochloride 100 mg
Study: NCT03933930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactate-directed therapy
Description: If the lactate level elevates, we transfuse pRBC to increase Hct\>30%. If Hct \>30%, dopamine infusion starts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
Study: NCT03384134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Buddy
Description: Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
Study: NCT03279263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLR-1023
Description: MLR-1023 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLR-1023
Description: MLR-1023 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLR-1023
Description: MLR-1023 Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablets
Study: NCT06593730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 0.5%w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 0.75%w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 1.0%w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 1.5%w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 2.0%w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 2.5%w/w
Study: NCT04162613

Intervention type: OTHER
Intervention: Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation
Description: The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level.
Study: NCT03479255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-enabled structured exercise therapy (SE-SET)
Description: The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise therapy
Description: The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
Study: NCT04389736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Description: Participants sat in a chair with back, arms and legs supported.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected maximal intensity of neuromuscular electrical stimulation
Description: Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
Study: NCT02411500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
Study: NCT00153504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing and Health Study housing rental assistance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard local practice housing assistance
Study: NCT00383136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban high-bolus dose regimen
Description: bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
Study: NCT01217957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study: NCT03525678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin frozen liquid
Description: Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin frozen liquid
Description: Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin lyophilized powder
Description: Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
Study: NCT02633124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edelvaiss Multiline NEO
Description: Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Infusion Set
Description: Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
Study: NCT03666754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy arm
Description: Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early endovenous glue embolization arm
Description: Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
Study: NCT01582477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 20 mL
Description: EXPAREL 266 mg (undiluted)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL 40 mL
Description: EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
Study: NCT02886819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: Whole body vibration
Study: NCT04133818

Intervention type: BEHAVIORAL
Intervention: Multidisciplinary education and exercise therapy program
Description: Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation